NCT01123772View on ClinicalTrials.gov

Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Health
Interventions
DRUG

INO-8875

eye drops for 14 days in one eye

OTHER

Placebo control

Matched placebo

Trial Locations (1)

Unknown

Evansville

Sponsors
All Listed Sponsors
lead

Inotek Pharmaceuticals Corporation

INDUSTRY